$1.65
65.31% today
Nasdaq, Apr 02, 09:46 pm CET
ISIN
US03835L1089
Symbol
APVO
Sector
Industry

Aptevo Therapeutics Inc Stock price

$1.00
-2.09 67.70% 1M
-5.22 83.95% 6M
-3.31 76.84% YTD
-156.25 99.37% 1Y
-10,255.40 99.99% 3Y
-5,745.84 99.98% 5Y
-182,335.00 100.00% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.16 13.96%
ISIN
US03835L1089
Symbol
APVO
Sector
Industry

Key metrics

Market capitalization $1.46m
Enterprise Value $-2.62m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF 0.11
P/B ratio (TTM) P/B ratio 0.31
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-24.60m
Free Cash Flow (TTM) Free Cash Flow $-23.79m
Cash position $8.71m
EPS (TTM) EPS $-452.26
Short interest 8.27%
Show more

Is Aptevo Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Aptevo Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aptevo Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aptevo Therapeutics Inc:

Buy
100%

Financial data from Aptevo Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.27 0.27
53% 53%
-
- -
-
-
- Selling and Administrative Expenses 10 10
9% 9%
-
- Research and Development Expense 14 14
15% 15%
-
-24 -24
14% 14%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -25 -25
15% 15%
-
Net Profit -24 -24
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptevo Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptevo Therapeutics Inc Stock News

Neutral
Accesswire
13 days ago
Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform doublet combination benchmark No Cytokine Release Syndrome (CRS) has been observed in the RAINIER trial to date Cohort 2 enrollment nears completion SEATTLE, WA / ACCESS Newswire / March 20, 2025 / ...
Neutral
Accesswire
15 days ago
Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a leader in the development of novel bispecific antibodies for cancer treatment, based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies provided an overview of solid tumor anti-canc...
Neutral
Accesswire
27 days ago
SEATTLE, WA / ACCESS Newswire / March 6, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced that the Company is participating in two conferences in March, as follows: The 37th Annual Roth Conference March 16-18, 20...
More Aptevo Therapeutics Inc News

Company Profile

Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Marvin White
Employees 42
Founded 2016
Website www.aptevotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today